Skip to content

Released Aug 9, 2018, after the close

10-Q filed Aug 9, 2018, 40 days after period end · 0001564590-18-021018

Q2 2018 · 10-Q
Revenue$463.00K+85.9% vs Q2 2017−59.8% vs Q1 2018
Net Income-$9.96MN/M vs Q2 2017N/M vs Q1 2018
EPS Diluted-$0.69N/M vs Q2 2017N/M vs Q1 2018
Operating Income-$9,971,000N/M
Operating Cash Flowderived-$8,641,000N/M
Margins · derived
Operating margin-2153.6%+1928.8 pt vs Q2 2017
Net margin-2150.3%+1532.0 pt vs Q2 2017

What the release said

The release

Same quarter

MetricQ2 2018Q2 2017Q2 2016
Revenue$463.00K$249.00K—
Net Income-$9.96M-$9.17M-$6.06M
EPS Diluted-$0.69-$36.21-$25.30

The same fiscal quarter, prior years. Thaler holds no estimates to compare against.

Spero Therapeutics, Inc. · CIK 1701108 · Engraved from SEC EDGAR